Srinivas Rao - 13 Mar 2024 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)

Role
Co-Founder & Chief Scientific Officer
Signature
/s/ Ryan Barrett , Attorney-in-fact
Issuer symbol
ATAI
Transactions as of
13 Mar 2024
Net transactions value
$0
Form type
4
Filing time
15 Mar 2024, 20:16:18 UTC
Previous filing
16 Mar 2023
Next filing
04 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATAI Common Shares Options Exercise +175,000 175,000 14 Mar 2024 Direct F1
holding ATAI Common Shares 3,500 13 Mar 2024 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATAI Stock Option Award $0 +800,000 $0.000000 800,000 13 Mar 2024 Common Shares 800,000 $1.84 Direct F2
transaction ATAI Restricted Stock Units Options Exercise $0 -175,000 -50% $0.000000 175,000 14 Mar 2024 Common Shares 175,000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date.
F2 The stock option shall vest as to 25% of the underlying shares on January 1, 2025, and in 36 substantially equal monthly installments thereafter.

Remarks:

Co-Founder & Chief Scientific Officer